Japan colorectal tumor prevention study: clinical trial by low-dose aspirin(100 mg/day) - Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study II)

Ishikawa Hideki0 sites4,500 target enrollmentMarch 25, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 25, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Ishikawa Hideki

•Candidate patients have to meet all the following inclusion criteria to participate in the study.
•\# Patients with at least one colorectal tumor (intramucosal cancer and adenoma) as confirmed by histological diagnosis, all of which have been removed endoscopically including the past.
•\# Patients with known history of all endoscopic treatments (including histological diagnosis) of colorectal tumors. Patients without histological diagnosis but have histological sections could participate in the trial.
•\# Patients who have undergone total colonoscopy at least twice.
•\# Patients with clean colon as confirmed by total colonoscopy within 3 months before the study. All histological diagnosis of the colorectal polyps should be done before the trial start.

•\# Patients with a medical history of submucosal (sm) or deeper colorectal cancer.
•\# Patients with familial adenomatous polyposis or Lynch syndrome.
•\# Patients currently taking antithrombotics such as Bayaspirin, Panaldine, Warfarin and Persantin etc.
•\# Patients with known allergy to aspirin.
•\# Patients who have undergone colorectal resection (those who have undergone appendectomy are allowed to participate in the study).
•\# Women who are or may be pregnant during the study period.
•\# Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study)
•\# Patients with inflammatory bowel disease (ulcerative colitis, Crohn syndrome), bleeding diverticulosis, bleeding gastritis.
•\# Patients with bleeding tendency, a platelet count of \< 100,000 /mm3, or with abnormal prothrombin time.
•\# Patients with any existing cancer at the time of participation in the study.